Seeking Alpha

The FDA accepts Biogen's (BIIB) application for the approval of the company's Recombinant FIXFc...

The FDA accepts Biogen's (BIIB) application for the approval of the company's Recombinant FIXFc clotting drug to treat hemophilia B and grants a standard review timeline. Biogen says Recombinant FIXFc will allow less frequent injections for patients and cut bleeding rates. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|